Literature DB >> 16510639

Prophylaxis with acetaminophen or ibuprofen for prevention of local reactions to the fifth diphtheria-tetanus toxoids-acellular pertussis vaccination: a randomized, controlled trial.

Lisa A Jackson1, Maya Dunstan, Patty Starkovich, John Dunn, Onchee Yu, Jennifer C Nelson, Thom Rees, Ann Zavitkovsky.   

Abstract

BACKGROUND: The frequency of local vaccination reactions increases with successive doses of diphtheria-tetanus toxoids-acellular pertussis (DTaP) vaccine, and local reactions occur for the majority of children receiving the fifth DTaP vaccination. It is not known whether these reactions can be prevented with prophylactic use of acetaminophen or ibuprofen.
METHODS: In this 3-group, randomized, blinded, controlled trial, 372 children were assigned randomly, in a 2:2:1 ratio, to receive 3 doses of acetaminophen, ibuprofen, or placebo. The first dose of study medication was administered within 2 hours before the fifth DTaP vaccination, and the remaining 2 doses were given at 6-hour intervals. The primary outcome measures included a local reaction with an area of redness or discoloration > or =5 cm in diameter on the evening of or during the 2 days after vaccination, an increase in mid-limb circumference of > or =2 cm on the evening of or during the 2 days after vaccination, and a persistent local reaction, defined as an area of redness or discoloration present on the third day after vaccination.
RESULTS: Local reactions with a > or =5-cm area of redness or discoloration were reported for 35% of children in the placebo group, compared with 33% of children in the acetaminophen group and 37% of children in the ibuprofen group. There was also no significant difference between the placebo and treatment groups in the proportions of children with a > or =2-cm increase in mid-limb circumference or with a persistent local reaction.
CONCLUSIONS: We did not find evidence that prophylaxis with acetaminophen or ibuprofen offers a clinically significant benefit in prevention of local reactions to the fifth DTaP vaccination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510639     DOI: 10.1542/peds.2005-1217

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

1.  Prophylactic use of acetaminophen in children vaccinated with diphtheria-tetanus-pertussis.

Authors:  S Songül Yalçin; Ayça Gümüş; Kadriye Yurdakök
Journal:  World J Pediatr       Date:  2008-05       Impact factor: 2.764

Review 2.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

Review 3.  The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: a systematic review.

Authors:  Rashmi Ranjan Das; Inusha Panigrahi; Sushree Samiksha Naik
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

4.  Effects of Administering Prophylactic Acetaminophen on Short-term Complications of Vaccination in 6-month-old Infants.

Authors:  Mohammad Mehdi Karambin; Abtin Heidarzadeh; Rose Sharghy; Setila Dalili; Houman Hashemian
Journal:  Int J Prev Med       Date:  2015-12-21

5.  An open-label randomized clinical trial of prophylactic paracetamol coadministered with 7-valent pneumococcal conjugate vaccine and hexavalent diphtheria toxoid, tetanus toxoid, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b vaccine.

Authors:  Markus A Rose; Christine Juergens; Beate Schmoele-Thoma; William C Gruber; Sherryl Baker; Stefan Zielen
Journal:  BMC Pediatr       Date:  2013-06-21       Impact factor: 2.125

6.  Knowledge, attitudes and misconceptions of primary care physicians regarding fever in children: a cross sectional study.

Authors:  Figen Demir; Ozgur Sekreter
Journal:  Ital J Pediatr       Date:  2012-09-05       Impact factor: 2.638

7.  Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials.

Authors:  Anne M C M Doedée; Greet J Boland; Jeroen L A Pennings; Arja de Klerk; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker; Henk van Loveren; Riny Janssen
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.